T1	Participants 233 310	92 outpatients affected by generalized anxiety disorders for at least 1 month
T2	Participants 357 422	47 patients were randomized to ketazolam 15 mg, and 45 to placebo
T3	Participants 854 926	Seventy-eight patients completed the first period and 75 the whole study
